We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nouveau Life Pharmaceuticals Inc (PK) | USOTC:NOUV | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0001 | 0.0001 | 0.0002 | 0.0001 | 0.0001 | 0.0001 | 1,345,000 | 12:09:51 |
DALLAS, TX -- October 30, 2019 -- InvestorsHub NewsWire -- Puration, Inc. (PURA) reminds investors today that the company will rollout plans for its THC Savor beverage in Canada tomorrow, Thursday, October 31, 2019. With Canada legalizing cannabis infused beverages this month, PURA is moving forward with its already designed THC Savor beverage. PURA has already designed a THC infused beverage named THC Savor, and with its Nouveau (NOUV) partner that already has a presence in Canada, PURA has a foot in the door, but tune-in tomorrow to hear more.
PURA realized $1 million in revenue last year in 2018 and then reported another $1 million in revenue in just the first six months of 2019. PURA management has set a $4 million revenue target for year-end 2019. With PURA’s growing number of new distribution agreements in strategic markets, a recent analyst projection has PURA reaching $8 million in revenue in 2020.
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
1 Year Nouveau Life Pharmaceuti... (PK) Chart |
1 Month Nouveau Life Pharmaceuti... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions